Development of gene sequencing technology and its application and challenges in tumor liquid biopsy
10.3760/cma.j.cn114452-20240912-00510
- VernacularTitle:基因测序技术发展及其在肿瘤液体活检中的应用与挑战
- Author:
Mengxiao XIE
1
;
Shiyang PAN
Author Information
1. 南京医科大学第一附属医院检验学部，国家医学检验临床医学研究中心分中心，南京210029
- Keywords:
Neoplasms;
Sequencing;
Liquid biopsy;
Circulating tumor DNA;
Circulating tumor cell
- From:
Chinese Journal of Laboratory Medicine
2024;47(11):1231-1236
- CountryChina
- Language:Chinese
-
Abstract:
Sequencing is becoming increasingly important in the early detection, companion diagnostics, molecular subtyping, and prognosis assessment of malignant tumors. In this special column of'tumors and sequencing′, renowned experts in the field of laboratory medicine elaborate on cutting-edge concepts, technologies, and applications related to drug target gene and polymorphism analysis, novel techniques of liquid biopsy, and the clinical cases of mutated genes in solid tumors and hematoma. Notably, liquid biopsy techniques based on circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) are advancing rapidly, offering the potential to serve as non-invasive diagnostic tools that facilitate precision medicine in oncology. To address the limitations of current ctDNA next-generation sequencing (NGS), future developments may focus on NGS targeting CTC-DNA for more precise tumor-targeted therapy. Despite the progress, challenges remain in integrating oncogene sequencing into clinical laboratories and advancing laboratory medicine. Addressing these challenges is crucial to improving public health.
